PapersFlow Research Brief
Hepatitis B Virus Studies
Research Guide
What is Hepatitis B Virus Studies?
Hepatitis B Virus Studies is the body of research examining the epidemiology, clinical management, antiviral therapy, and global burden of hepatitis B virus (HBV) infection, including chronic hepatitis B, hepatocellular carcinoma, vaccine prevention, and immune responses.
This field encompasses 153,713 published works on HBV-related topics such as viral hepatitis, liver disease, and antiviral therapy. Key contributions include clinical practice guidelines for managing hepatocellular carcinoma, a major complication of chronic HBV, as detailed in 'EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma' (2018) with 11,188 citations. Research also addresses HBV isolation and treatment updates, exemplified by foundational papers like 'Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome' (1989) with 6,872 citations.
Topic Hierarchy
Research Sub-Topics
Epidemiology of Chronic Hepatitis B
Epidemiologists track HBV prevalence, genotypes, transmission modes, and risk factors in global populations using serosurveys and cohort studies. Modeling estimates disease burden and vaccination impacts across regions.
HBV-Associated Hepatocellular Carcinoma
Oncologists study viral integration mechanisms, carcinogenic pathways, and surveillance protocols for HCC in HBV patients. Clinical trials evaluate antiviral effects on cancer incidence and outcomes.
Antiviral Therapy for HBV Infection
Clinical researchers assess nucleos(t)ide analogs and interferons for viral suppression, resistance prevention, and treatment cessation criteria. Long-term trials monitor renal, bone, and flare risks.
Immune Response to Hepatitis B Virus
Immunologists dissect T-cell exhaustion, B-cell responses, and innate immunity in acute versus chronic HBV. Checkpoint inhibitors and therapeutic vaccines are tested to restore control.
Hepatitis B Vaccine Prevention Strategies
Public health experts evaluate vaccine efficacy, schedules, and coverage in perinatal, pediatric, and adult populations. Studies address breakthrough infections, durability, and booster needs.
Why It Matters
Hepatitis B Virus Studies directly informs clinical management of chronic HBV infection and its progression to hepatocellular carcinoma (HCC), affecting global liver disease burdens. 'EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection' by Lampertico et al. (2017, 5,282 citations) provides evidence-based strategies for antiviral therapy and monitoring, reducing HCC risk in chronic patients. 'Management of Hepatocellular Carcinoma: An Update' by Bruix and Sherman (2011, 8,064 citations) updates diagnostic and treatment protocols post-2005 AASLD guidelines, incorporating transarterial chemoembolization and liver transplantation for HBV-related HCC. Recent news highlights GSK's positive phase III results for bepirovirsen in B-Well 1 and B-Well 2 trials (2026), meeting primary endpoints as a potential first-in-class treatment, while CDC's $1.6 million grant supports hepatitis B vaccine studies.
Reading Guide
Where to Start
'EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection' by Lampertico et al. (2017) – provides a structured clinical overview of HBV management, antiviral indications, and monitoring, serving as an accessible entry for understanding core principles before diving into HCC or molecular studies.
Key Papers Explained
'EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma' by Galle et al. (2018) builds on 'Management of Hepatocellular Carcinoma: An Update' by Bruix and Sherman (2011), which updates the 2005 'Management of Hepatocellular Carcinoma' by Bruix and Sherman, refining staging and therapies like TACE for HBV-related HCC. 'EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection' by Lampertico et al. (2017) integrates HBV-specific prevention to reduce HCC incidence addressed in Forner et al.'s 'Hepatocellular carcinoma' (2018). These form a progression from foundational isolation in Choo et al. (1989) to modern guidelines.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Preprints on siRNA therapies like 'An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection' target HBsAg suppression for immune restoration, while 'Elebsiran and PEG-IFNα for chronic hepatitis B infection' evaluates phase 2 combinations. GSK's bepirovirsen phase III success in B-Well trials (2026) advances functional cure candidates. Tools like HBV-GLUE enable comparative genomics of HBV sequences.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | EASL Clinical Practice Guidelines: Management of hepatocellula... | 2018 | Journal of Hepatology | 11.2K | ✓ |
| 2 | Human papillomavirus is a necessary cause of invasive cervical... | 1999 | The Journal of Pathology | 8.9K | ✕ |
| 3 | Management of Hepatocellular Carcinoma: An Update Δσ | 2011 | Hepatology | 8.1K | ✓ |
| 4 | Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, No... | 1989 | Science | 6.9K | ✕ |
| 5 | Epidemiologic Classification of Human Papillomavirus Types Ass... | 2003 | New England Journal of... | 6.2K | ✓ |
| 6 | Peginterferon alfa-2b plus ribavirin compared with interferon ... | 2001 | The Lancet | 6.0K | ✕ |
| 7 | Management of Hepatocellular Carcinoma * | 2005 | Hepatology | 5.9K | ✓ |
| 8 | Hepatocellular carcinoma | 2018 | The Lancet | 5.4K | ✕ |
| 9 | Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma | 2017 | Case Reports in Gastro... | 5.4K | ✓ |
| 10 | EASL 2017 Clinical Practice Guidelines on the management of he... | 2017 | Journal of Hepatology | 5.3K | ✕ |
In the News
CDC awards $1.6 million for hepatitis B vaccine study by ...
The US Centers for Disease Control and Prevention (CDC) has awarded an unsolicited $1.6 million grant for vaccine research to Danish researchers whose studies have been challenged by mainstream sci...
Is this controversial U.S.-funded vaccine trial on or off?
The randomized controlled trial —funded partly with $1.6 million from the U.S. Centers for Disease Control and Prevention —would study the general health effects of the hepatitis B vaccine given at...
GSK announces positive results from B-Well 1 and B- ...
# GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B Download(PDF - 211.1KB) * **Primary end...
Ionis partner GSK announces positive topline results from ...
GSK licensed bepirovirsen from Ionis in 2019 under a collaborative development and licensing agreement. Under the terms of the agreement, Ionis received an upfront payment, license fee and developm...
Taiwanese scientist conducting influential hepatitis ...
# Taiwanese scientist conducting influential hepatitis research to receive the 2025 Baruch S. Blumberg Prize
Code & Tools
HBV-GLUE is a sequence-oriented resource for comparative genomic analysis of hepatitis B virus (HBV), developed using the GLUE software framework.
* **GLUE Framework Integration**: Built on the GLUE software framework, Hepadnavirus-GLUE offers an extensible platform for efficient, standardized...
VIRiONT pipeline is designed to analyze data from amplicon-approach-based Nanopore sequencing. It was primarily developed to analyze data from hepa...
html_document: default word_document: default require(ggplot2) require(plotly) require(psych) require(rattle) library(caret) MACHINE LEARNING E...
| `EV` | Picornaviridae | Enteroviruses (Coxsackie, Polio, Rhino, etc.), Parecho, Aichi, Hepatitis A | | `RVA` | _Rotavirus A_ | Rotavirus A | | `H...
Recent Preprints
Viral sequence analysis of chronic hepatitis B patients ...
Small-interfering RNA (siRNA) therapy with JNJ-3989 in patients with chronic hepatitis B induces potent, dose-dependent reductions in viral antigens, though the magnitude of decline varies among in...
An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection
Current therapeutics for chronic hepatitis B virus (HBV) infection are insufficient due to immune exhaustion caused by high circulating hepatitis B surface antigen (HBsAg) levels. Here, an HBV S re...
Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial
Functional cure is a goal for the treatment of chronic hepatitis B virus (HBV) infection; however, it is infrequently achieved with currently approved treatments. Here we provide a randomized evalu...
Optimal strategies for managing Hepatitis B Virus (HBV) ...
Hepatitis B virus (HBV) is a significant health hazard in the world. This article describes a new mathematical model, which takes into account three intervention measures: education, vaccination, a...
Novel insights into chronic HBV infection
Chronic hepatitis B infection remains the dominant aetiology of liver-related complications and hepatocellular carcinoma. In 2025, key evidence emerged supporting the expansion of treatment criteri...
Latest Developments
Recent developments in hepatitis B research include the announcement by GSK of a new drug candidate, bepirovirsen, showing positive results in phase 2 trials aimed at a functional cure (science.org, published January 9, 2026). Additionally, advances in 2024 have improved understanding of CD8+ T cell dysfunction, and new therapeutic approaches such as viral entry inhibitors, epigenetic control of cccDNA, immune modulators, RNA interference techniques, and capsid assembly modulators are being developed (nature.com, August 29, 2025; pmc.ncbi.nlm.nih.gov, February 2026). Other promising research includes therapeutic vaccines entering clinical trials and novel insights into the virus's molecular mechanisms, which could lead to new treatments (mskcc.org, February 20, 2025; nature.com, December 1, 2025).
Sources
Frequently Asked Questions
What are the EASL guidelines for managing HBV infection?
'EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection' by Lampertico et al. (2017) outlines antiviral therapy indications, monitoring for chronic HBV, and prevention of complications like HCC. These guidelines emphasize nucleos(t)ide analogues and peginterferon for eligible patients. They serve as a standard for clinical practice in HBV management.
How is hepatocellular carcinoma managed in HBV patients?
'EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma' by Galle et al. (2018, 11,188 citations) recommends staging, surveillance, and treatments like resection, ablation, and embolization for HBV-associated HCC. 'Management of Hepatocellular Carcinoma: An Update' by Bruix and Sherman (2011, 8,064 citations) details performance status-based approaches including radiofrequency ablation and transplantation. These protocols improve survival rates in HBV-linked cases.
What role did Choo et al. play in HBV research?
'Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome' by Choo et al. (1989, 6,872 citations) isolated a cDNA clone from non-A, non-B hepatitis plasma, identifying antigens specific to the virus later confirmed as HCV, advancing viral hepatitis diagnostics. This work enabled PCR-based detection methods. It foundational for distinguishing HBV from other hepatitides.
What are current antiviral therapies for chronic HBV?
'EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection' (2017) endorses tenofovir and entecavir as first-line therapies for suppressing HBV DNA in chronic infection. Recent preprints describe siRNA agents like JNJ-3989 inducing dose-dependent HBsAg reductions. Combination regimens with PEG-IFNα, as in elebsiran trials, aim for functional cure.
How does HBV contribute to hepatocellular carcinoma?
'Hepatocellular carcinoma' by Forner et al. (2018, 5,427 citations) links chronic HBV to HCC development via persistent inflammation and integration. 'Management of Hepatocellular Carcinoma' by Bruix and Sherman (2005, 5,856 citations) stresses surveillance in HBV carriers using ultrasound and AFP. Early detection enables curative interventions like resection.
Open Research Questions
- ? How can siRNA therapies like JNJ-3989 or elebsiran consistently achieve functional cure rates beyond current antivirals in chronic HBV patients?
- ? What baseline viral polymorphisms predict variable HBsAg and HBeAg responses to siRNA treatments in diverse HBV populations?
- ? Which combination regimens of RNA interference agents with PEG-IFNα optimize immune restoration for HBV clearance?
- ? How do mathematical models incorporating education, vaccination, and therapy best reduce global HBV incidence?
- ? What low-risk chronic HBV profiles allow safe expansion of treatment criteria without universal therapy?
Recent Trends
siRNA therapies have advanced with preprints showing JNJ-3989's dose-dependent HBsAg reductions without baseline polymorphisms explaining variability; elebsiran plus PEG-IFNα in phase 2 trials targets functional cure.
GSK reported positive topline results for bepirovirsen in B-Well 1 and 2 phase III trials, meeting primary endpoints.
2026CDC awarded $1.6 million for hepatitis B vaccine studies , amid debates on trial designs.
2025Research Hepatitis B Virus Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hepatitis B Virus Studies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers